Cellectis S.A. (EPA:ALCLS)
France · Delayed Price · Currency is EUR 2.542
-0.048 (-1.85%)
Jul 13, 2026, 5:35 PM CET
Cellectis Market Cap
Cellectis has a market cap or net worth of €184.55 million as of July 13, 2026. Its market cap has increased by 85.53% in one year.
Market Cap
184.55M
Enterprise Value
95.14M
Revenue
65.14M
Ranking
n/a
PE Ratio
n/a
Stock Price
€2.54
Market Cap Chart
Since February 7, 2007, Cellectis's market cap has increased from 100.59M to 184.55M, an increase of 83.46%. That is a compound annual growth rate of 3.17%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 13, 2026 | 184.55M | -39.17% |
| Dec 31, 2025 | 303.40M | 158.68% |
| Dec 31, 2024 | 117.29M | -40.86% |
| Dec 29, 2023 | 198.32M | 118.98% |
| Dec 30, 2022 | 90.57M | -73.23% |
| Dec 31, 2021 | 338.35M | -67.37% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Genfit | 687.33M |
| Valneva SE | 413.24M |
| Valerio Therapeutics Société anonyme | 224.75M |
| Transgene | 207.33M |
| Innate Pharma | 147.69M |
| Sensorion | 133.83M |
| OSE Immunotherapeutics | 78.13M |
| Adocia | 73.18M |